The Canaccord report is 38 pages long but includes 4 pages of disclosures/disclaimers. It's primarily a note on HPA.
ADN commentary is mainly based on the scoping study. My guess is that if you knew nothing about ADN beforehand there's nothing in the report that would encourage you to buy.
This flowsheet is from the ADN PFS.
This is from P.17 of the Canaccord report.
OTOH it's great to see an industry/sector piece.
You can see where the main thrust of the report is from the Table of Contents. The three potential HPA producers covered in the report are Alpha, Altech & FYI. I suspect that when ADN announces a clear path to HPA production the tenor of the research in favour of ADN will change substantially.
As I said, a good sector report although I know nothing about the other companies covered in the report.
Buy ADN for HPA? Sure can!
General comments/chat, page-25631
Add ADN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.001(16.7%) |
Mkt cap ! $24.00M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.6¢ | $4.903K | 748.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 17955019 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 9103740 | 27 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| ADN (ASX) Chart |